Table 3.
Presence of antibodies against SARS‐CoV‐2 in patients with different clinical types at different stage after onset
| Moderate/severe cases | Mild Cases | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days after onset | IgM | IgG | IgM or IgG | IgM | IgG | IgM or IgG | ||||||||||||
| Positive | Negative | Sensitivity (%) | Positive | Negative | Sensitivity (%) | Positive | Negative | Sensitivity (%) | Positive | Negative | Sensitivity (%) | Positive | Negative | Sensitivity (%) | Positive | Negative | Sensitivity (%) | |
| 1–7 | 52 | 62 | 45.61 | 54 | 60 | 47.37 | 64 | 50 | 56.14 | 4 | 5 | 44.44 | 5 | 4 | 55.56 | 5 | 4 | 55.56 |
| 8–14 | 60 | 9 | 86.96 | 61 | 8 | 88.41 | 63 | 6 | 91.30 | 9 | 6 | 60.00 | 11 | 4 | 73.33 | 11 | 4 | 73.33 |
| 15–21 | 68 | 4 | 94.44 | 71 | 1 | 98.61 | 71 | 1 | 98.61 | 7 | 1 | 87.50 | 8 | 0 | 100.00 | 8 | 0 | 100.00 |
| 22–28 | 73 | 6 | 92.41 | 77 | 2 | 97.47 | 77 | 2 | 97.47 | 28 | 9 | 75.68* | 34 | 3 | 91.89 | 35 | 2 | 94.59 |
| 29–35 | 89 | 9 | 90.82 | 98 | 0 | 100.00 | 98 | 0 | 100.00 | 25 | 9 | 73.53* | 32 | 2 | 94.12 | 32 | 2 | 94.12 |
| 36–42 | 57 | 7 | 89.06 | 61 | 3 | 95.31 | 61 | 3 | 95.31 | 34 | 3 | 91.89 | 36 | 1 | 97.30 | 36 | 1 | 97.30 |
| >42 | 69 | 19 | 78.41 | 85 | 3 | 96.59 | 85 | 3 | 96.59 | 8 | 1 | 88.89 | 8 | 1 | 88.89 | 8 | 1 | 88.89 |
Abbreviations: IgG, immunoglobulin G; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
*
p < .05 (mild cases vs. moderate/severe cases).